Market Research Logo

Global DNA Vaccine Market Insights, Opportunity, Analysis, Market Shares And Forecast 2017 – 2023

Global DNA Vaccine Market Insights, Opportunity, Analysis, Market Shares And Forecast 2017 – 2023

DNA vaccine technology is a third-generation vaccine technology that introduces host animal with a genetic material of disease-causing pathogen. This genetic material helps to strengthen the immune system by forming a protective protein that enables effective immune response against a disease-causing antigen. Global DNA vaccine market is anticipated to rise with a CAGR of about 55% during the forecast years 2016-2023. Increasing adoption of DNA vaccines for animal healthcare is driving the global DNA vaccines market. Some other factors that includes rising prevalence of chronic and infectious diseases, surging investments in the development of third generation vaccination technology and low cost of DNA vaccines as compared to other gene therapy technologies also helps to drive the market growth.

The global DNA vaccine market is segmented on the basis of geography into North America, Europe, Asia Pacific and rest of the world. Asia pacific market is estimated to grow at a fast pace as compared to other regions due to rising awareness among consumers regarding the advantages of immunization in case of H1N1 influenza and Hepatitis B. For instance, State food and drug administration in China has designated 11 biotech companies for the development of H1N1 influenza vaccine. North America region dominates the majority of market revenue among other regions. Increasing prevalence of infectious and chronic diseases in countries such as US and Canada is driving the demand of effective vaccination technology. Mortality rate due to chronic and infectious disease has increased in the United States to about 360,000 every year.

The global DNA vaccine market has been segmented on the basis of type of DNA vaccines, technology and applications. On the basis of application, the market has been segmented into human disease applications and veterinary disease applications market. Among these, the veterinary applications are leading the DNA vaccine market due to availability of DNA vaccines for animal diseases that includes canine melanoma vaccine (for DOG), West Nile Innovator (for Horse), Life tide-SW5 (for Swine and other food animals) and Apex-IHN (for Salmon fish). Among the segment of DNA vaccine type, Animal DNA vaccine is a leading the market due to unavailability of human DNA vaccines in the market along with rising incidence of canine melanoma and other animal diseases. Canine melanoma accounts to about 7% of all canine skin tumours cases globally. Moreover, after the entry of human DNA vaccines, this segment is expected to grow at a fast pace.

The major market players of the global DNA vaccine market include Novartis Animal Health, Inovio Biomedical Corp., Merck & Co., Vical Inc., Dendreon Corporation, Astellas Pharma, Sanofi, Tekmira Pharmaceuticals, GlaxoSmithKline Inc., Pfizer Pharmaceuticals, Advance Bioscience Laboratories Inc., Indian Immunologicals Ltd., Xenetic Biosciences Inc., QED Biosciences Inc., Tolerion Inc. and Others. These companies using various strategies such as merger & acquisition, collaboration, partnership and product launch. Whereas, merger & acquisition is the key strategy adopted by the companies in the global DNA vaccine market.

For example, On 14th January 2015, Vical and AnGes announced a collaboration for the development of Ebola virus disease therapy. Vical will develop and provide a DNA vaccine by encoding the glycoprotein antigen of zaire strain of Ebola virus to AnGes. Vical's proprietary Vaxfectin® adjuvant will help in the formulation of vaccine. AnGes will be granted with the right regarding development and commercialization of the equine polyclonal antibody therapy in Japan and will bear all the development costs. Vical will be receiving an upfront payment and royalties on net sales.

Please note: The delivery time for the electronic version of this report is between 1-3 business days to allow the preparation of an updated version prior to dispatch.


1. INTRODUCTION
1.1. EXECUTIVE SUMMARY
1.2. ESTIMATION METHODOLOGY
2. MARKET OVERVIE.
2.1. GLOBAL DNA VACCINES MARKET: EVOLUTION & TRANSITION
2.2. MARKET DEFINITION AND SCOPE
2.3. INDUSTRY STRUCTURE
2.4. REGULATORY FRAMEWORK
2.5. TOTAL MARKET ANALYSIS
2.5.1. TOP 5 FINDINGS
2.5.2. TOP 5 OPPORTUNITY MARKETS
2.5.3. TOP 5 COMPANIES
2.5.4. TOP 3 COMPETITIVE STRATEGIES
2.6. ESTIMATION ANALYSIS
2.7. STRATEGIC ANALYSIS
2.7.1. INVESTMENT VS. ADOPTION MODEL
2.7.2. 360 DEGREE INDUSTRY ANALYSIS
2.7.3. PORTERS 5 FORCE MODEL
2.7.4. SEE-SAW ANALYSIS
2.7.5. CONSUMER ANALYSIS AND KEY BUYING CRITERIA
2.8. COMPETITIVE ANALYSIS
2.8.1. KEY STRATEGIES AND ANALYSIS
2.8.2. MARKET SHARE AND TOP COMPANY ANALYSIS
2.9. STRATEGIC RECOMMENDATIONS & KEY CONCLUSIONS
2.9.1. INVESTMENT OPPORTUNITIES BY REGIONS
2.9.2. OPPORTUNITIES IN EMERGING APPLICATIONS
2.9.3. INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT
3. MARKET DETERMINANT.
3.1. MARKET DRIVERS
3.1.1. RISING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES
3.1.2. SURGING INVESTMENTS IN THE DEVELOPMENT OF THIRD GENERATION VACCINATION TECHNOLOGY
3.1.3. INCREASING ADOPTION OF DNA VACCINES FOR ANIMAL HEALTHCARE
3.1.4. LOW COST OF DNA VACCINES AS COMPARED TO OTHER GENE THERAPY TECHNOLOGIES.
3.2. MARKET RESTRAINTS
3.2.1. STRINGENT GOVERNMENT RULES AND REGULATIONS
3.2.2. LACK OF LEGAL AND ETHICAL FRAMEWORK IN DEVELOPING ECONOMIES
3.3. MARKET OPPORTUNITIES
3.3.1. INCREASING RESEARCH ON HUMAN CLINICAL TRIALS
3.3.2. RISING DEMAND OF GENE THERAPY
3.3.3. EASY STORAGE CAN BE BENEFICIAL IN DEVELOPING COUNTRIES
3.4. MARKET CHALLENGES
3.4.1. LACK OF AWARENESS TOWARDS GENE BASED VACCINATIONS
3.4.2. MANUFACTURING A SAFE AND EFFECTIVE PRODUCT WITH LESS SIDE EFFECTS
4.MARKET SEGMENTATIO.
4.1. GLOBAL DNA VACCINES MARKET BY TYPE
4.1.1. MARKET DEFINITION AND SCOPE
4.1.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.1.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.1.4. OPPORTUNITY MATRIX
4.1.5. MARKET SEGMENTATION
4.1.5.1. GLOBAL ANIMAL DNA VACCINES MARKET
4.1.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.5.1.3. TOP PLAYERS & KEY PRODUCTS
4.1.5.1.4. KEY CONCLUSIONS
4.1.5.2. GLOBAL HUMAN DNA VACCINES MARKET
4.1.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.5.2.3. TOP PLAYERS & KEY PRODUCTS
4.1.5.2.4. KEY CONCLUSIONS
4.1.5.2.5. KEY CONCLUSIONS
4.2. GLOBAL DNA VACCINES MARKET BY TECHNOLOGY
4.2.1. MARKET DEFINITION AND SCOPE
4.2.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.2.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.2.4. OPPORTUNITY MATRIX
4.2.5. MARKET SEGMENTATION
4.2.5.1. GLOBAL PLASMID DNA VACCINES TECHNOLOGY MARKET
4.2.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.1.3. TOP PLAYERS & KEY PRODUCTS
4.2.5.1.4. KEY CONCLUSIONS
4.2.5.2. GLOBAL PLASMID DNA DELIVERY TECHNOLOGY MARKET
4.2.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.2.3. TOP PLAYERS & KEY PRODUCTS
4.2.5.2.4. KEY CONCLUSIONS
4.3. GLOBAL DNA VACCINES MARKET BY APPLICATIONS
4.3.1. MARKET DEFINITION AND SCOPE
4.3.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.3.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.3.4. OPPORTUNITY MATRIX
4.3.5. MARKET SEGMENTATION
4.3.5.1. GLOBAL HUMAN DISEASES APPLICATIONS MARKET
4.3.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.1.3. TOP PLAYERS & KEY PRODUCTS
4.3.5.1.4. KEY CONCLUSIONS
4.3.5.1.5. SUBSEGMENTS
4.3.5.1.5.1. ONCOLOGY
4.3.5.1.5.2. INFECTIOUS DISEASE
4.3.5.1.5.3. ALLERGIES
4.3.5.1.5.4. OTHERS
4.3.5.2. GLOBAL VETERINARY DISEASES APPLICATIONS MARKET
4.3.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.2.3. TOP PLAYERS & KEY PRODUCTS
4.3.5.2.4. KEY CONCLUSIONS
4.3.5.2.5. SUB SEGMENTS
4.3.5.2.5.1. CANINE MELANOMA
4.3.5.2.5.2. LEISHMANIASIS
4.3.5.2.5.3. EQUINE WEST NILE VIRUS
4.3.5.2.5.4. OTHERS
5.COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
5.1.1. LIST OF MERGERS & ACQUISITION
5.1.2. LIST OF JOINT VENTURES
5.1.3. LIST OF PRODUCT LAUNCHES
5.1.4. LIST OF PARTNERSHIPS
6.GLOBAL DNA VACCINES MARKET BY REGION
6.1. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
6.2. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
6.3. OPPORTUNITY MATRIX
6.4. GEOGRAPHIC SEGMENTATION
6.4.1. NORTH AMERICA
6.4.1.1. INDUSTRY APPLICATION ANALYSIS
6.4.1.2. TOP COUNTRY ANALYSIS
6.4.1.2.1. U.S.
6.4.1.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.1.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.1.2.1.3. KEY CONCLUSIONS
6.4.1.2.2. CANADA
6.4.1.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.1.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.1.2.2.3. KEY CONCLUSIONS
6.4.2. EUROPE
6.4.2.1. INDUSTRY APPLICATION ANALYSIS
6.4.2.2. TOP COUNTRY ANALYSIS
6.4.2.2.1. UK
6.4.2.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.2.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.1.3. KEY CONCLUSIONS
6.4.2.2.2. FRANCE
6.4.2.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.2.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.2.3. KEY CONCLUSIONS
6.4.2.2.3. GERMANY
6.4.2.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.2.2.3.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.3.3. KEY CONCLUSIONS
6.4.2.2.4. SPAIN
6.4.2.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.2.2.4.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.4.3. KEY CONCLUSIONS
6.4.2.2.5. REST OF EUROPE
6.4.2.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.2.2.5.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.5.3. KEY CONCLUSIONS
6.4.3. ASIA PACIFIC
6.4.3.1. INDUSTRY APPLICATION ANALYSIS
6.4.3.2. TOP COUNTRY ANALYSIS
6.4.3.2.1. CHINA
6.4.3.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.3.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.1.3. KEY CONCLUSIONS
6.4.3.2.2. INDIA
6.4.3.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.3.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.2.3. KEY CONCLUSIONS
6.4.3.2.3. JAPAN
6.4.3.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.3.2.3.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.3.3. KEY CONCLUSIONS
6.4.3.2.4. AUSTRALIA
6.4.3.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.3.2.4.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.4.3. KEY CONCLUSIONS
6.4.3.2.5. REST OF ASIA PACIFIC
6.4.3.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.3.2.5.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.5.3. KEY CONCLUSIONS
6.4.4. ROW
6.4.4.1. INDUSTRY APPLICATION ANALYSIS
6.4.4.2. TOP COUNTRY ANALYSIS
6.4.4.2.1. LATIN AMERICA
6.4.4.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.4.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.4.2.1.3. KEY CONCLUSIONS
6.4.4.2.2. MIDDLE EAST & AFRICA
6.4.4.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.4.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.4.2.2.3. KEY CONCLUSIONS
7.COMPANY PROFILE.
7.1. NOVARTIS ANIMAL HEALTH
7.1.1. OVERVIEW
7.1.2. PRODUCT PORTFOLIO
7.1.3. KEY INNOVATION/FOCUS SECTOR
7.1.4. STRATEGIC INITIATIVES
7.1.5. SCOT ANALYSIS
7.1.6. STRATEGIC ANALYSIS
7.2. INOVIO BIOMEDICAL CORP
7.2.1. OVERVIEW
7.2.2. PRODUCT PORTFOLIO
7.2.3. KEY INNOVATION/FOCUS SECTOR
7.2.4. STRATEGIC INITIATIVES
7.2.5. SCOT ANALYSIS
7.2.6. STRATEGIC ANALYSIS
7.3. MERCK & CO.
7.3.1. OVERVIEW
7.3.2. PRODUCT PORTFOLIO
7.3.3. KEY INNOVATION/FOCUS SECTOR
7.3.4. STRATEGIC INITIATIVES
7.3.5. SCOT ANALYSIS
7.3.6. STRATEGIC ANALYSIS
7.4. DENDREON CORPORATION
7.4.1. OVERVIEW
7.4.2. PRODUCT PORTFOLIO
7.4.3. KEY INNOVATION/FOCUS SECTOR
7.4.4. STRATEGIC INITIATIVES
7.4.5. SCOT ANALYSIS
7.4.6. STRATEGIC ANALYSIS
7.5. ASTELLAS PHARMA
7.5.1. OVERVIEW
7.5.2. PRODUCT PORTFOLIO
7.5.3. KEY INNOVATION/FOCUS SECTOR
7.5.4. STRATEGIC INITIATIVES
7.5.5. SCOT ANALYSIS
7.5.6. STRATEGIC ANALYSIS
7.6. VICAL
7.6.1. OVERVIEW
7.6.2. PRODUCT PORTFOLIO
7.6.3. KEY INNOVATION/FOCUS SECTOR
7.6.4. STRATEGIC INITIATIVES
7.6.5. SCOT ANALYSIS
7.6.6. STRATEGIC ANALYSIS
7.7. SANOFI
7.7.1. OVERVIEW
7.7.2. PRODUCT PORTFOLIO
7.7.3. KEY INNOVATION/FOCUS SECTOR
7.7.4. STRATEGIC INITIATIVES
7.7.5. SCOT ANALYSIS
7.7.6. STRATEGIC ANALYSIS
7.8. TEKMIRA PHARMACEUTICALS
7.8.1. OVERVIEW
7.8.2. PRODUCT PORTFOLIO
7.8.3. KEY INNOVATION/FOCUS SECTOR
7.8.4. STRATEGIC INITIATIVES
7.8.5. SCOT ANALYSIS
7.8.6. STRATEGIC ANALYSIS
7.9. GLAXOSMITHKLINE INC.
7.9.1. OVERVIEW
7.9.2. PRODUCT PORTFOLIO
7.9.3. KEY INNOVATION/FOCUS SECTOR
7.9.4. STRATEGIC INITIATIVES
7.9.5. SCOT ANALYSIS
7.9.6. STRATEGIC ANALYSIS
7.10. PFIZER PHARMACEUTICALS
7.10.1. OVERVIEW
7.10.2. PRODUCT PORTFOLIO
7.10.3. KEY INNOVATION/FOCUS SECTOR
7.10.4. STRATEGIC INITIATIVES
7.10.5. SCOT ANALYSIS
7.10.6. STRATEGIC ANALYSIS
7.11. ADVANCE BIOSCIENCE LABORATORIES INC.
7.11.1. OVERVIEW
7.11.2. PRODUCT PORTFOLIO
7.11.3. KEY INNOVATION/FOCUS SECTOR
7.11.4. STRATEGIC INITIATIVES
7.11.5. SCOT ANALYSIS
7.11.6. STRATEGIC ANALYSIS
7.12. INDIAN IMMUNOLOGICALS LTD.
7.12.1. OVERVIEW
7.12.2. PRODUCT PORTFOLIO
7.12.3. KEY INNOVATION/FOCUS SECTOR
7.12.4. STRATEGIC INITIATIVES
7.12.5. SCOT ANALYSIS
7.12.6. STRATEGIC ANALYSIS
7.13. XENETIC BIOSCIENCES INC.
7.13.1. OVERVIEW
7.13.2. PRODUCT PORTFOLIO
7.13.3. KEY INNOVATION/FOCUS SECTOR
7.13.4. STRATEGIC INITIATIVES
7.13.5. SCOT ANALYSIS
7.13.6. STRATEGIC ANALYSIS
7.14. QED BIOSCIENCES INC.
7.14.1. OVERVIEW
7.14.2. PRODUCT PORTFOLIO
7.14.3. KEY INNOVATION/FOCUS SECTOR
7.14.4. STRATEGIC INITIATIVES
7.14.5. SCOT ANALYSIS
7.14.6. STRATEGIC ANALYSIS
7.15. TOLERION INC.
7.15.1. OVERVIEW
7.15.2. PRODUCT PORTFOLIO
7.15.3. KEY INNOVATION/FOCUS SECTOR
7.15.4. STRATEGIC INITIATIVES
7.15.5. SCOT ANALYSIS
7.15.6. STRATEGIC ANALYSIS
LIST OF TABLES
GLOBAL DNA VACCINES MARKET BY TYPE 2014-2023 ($ MILLION)
GLOBAL ANIMAL DNA VACCINES MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL HUMAN DNA VACCINES MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL DNA VACCINES MARKET BY TECHNOLOGY 2014-2023 ($ MILLION)
GLOBAL PLASMID DNA VACCINES TECHNOLOGY MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL PLASMID DNA DELIVERY TECHNOLOGY MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL DNA VACCINES MARKET BY APPLICATIONS 2014-2023 ($ MILLION)
GLOBAL HUMAN DISEASES APPLICATIONS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL VETERINARY DISEASES APPLICATIONS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
NORTH AMERICA DNA VACCINES MARKET 2014-2023 ($ MILLION)
EUROPE DNA VACCINES MARKET 2014-2023 ($ MILLION)
ASIA PACIFIC DNA VACCINES MARKET 2014-2023 ($ MILLION)
REST OF THE WORLD DNA VACCINES MARKET 2014-2023 ($ MILLION)
LIST OF FIGURES
GLOBAL ANIMAL DNA VACCINES MARKET 2014-2023 ($ MILLION)
GLOBAL HUMAN DNA VACCINES MARKET 2014-2023 ($ MILLION)
GLOBAL PLASMID DNA VACCINES TECHNOLOGY MARKET 2014-2023 ($ MILLION)
GLOBAL PLASMID DNA DELIVERY TECHNOLOGY MARKET 2014-2023 ($ MILLION)
GLOBAL HUMAN DISEASES APPLICATIONS MARKET 2014-2023 ($ MILLION)
GLOBAL VETERINARY DISEASES APPLICATIONS MARKET 2014-2023 ($ MILLION)
UNITED STATES (U.S.) DNA VACCINES MARKET 2014-2023 ($ MILLION)
CANADA DNA VACCINES MARKET 2014-2023 ($ MILLION)
UNITED KINGDOM (UK) DNA VACCINES MARKET 2014-2023 ($ MILLION)
FRANCE DNA VACCINES MARKET 2014-2023 ($ MILLION)
GERMANY DNA VACCINES MARKET 2014-2023 ($ MILLION)
SPAIN DNA VACCINES MARKET 2014-2023 ($ MILLION)
ITALY DNA VACCINES MARKET 2014-2023 ($ MILLION)
ROE DNA VACCINES MARKET 2014-2023 ($ MILLION)
INDIA DNA VACCINES MARKET 2014-2023 ($ MILLION)
CHINA DNA VACCINES MARKET 2014-2023 ($ MILLION)
JAPAN DNA VACCINES MARKET 2014-2023 ($ MILLION)
KOREA DNA VACCINES MARKET 2014-2023 ($ MILLION)
AUSTRALIA DNA VACCINES MARKET 2014-2023 ($ MILLION)
ROAPAC DNA VACCINES MARKET 2014-2023 ($ MILLION)
LATIN AMERICA DNA VACCINES MARKET 2014-2023 ($ MILLION)
MENA DNA VACCINES MARKET 2014-2023 ($ MILLION)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report